RET and lung carcinoma: Irrespectively, despite the individually low frequency of many potentially actionable variants defined in the current study (e.g. ERBB2, BRAF, RET, ROS1, PIK3CA), the high incidence of lung cancer implies that a large population worldwide is affected, supporting clinical trials or routine molecular screening programs in the disease [19].